Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination
PLOS One · 2025
DOI: 10.1371/journal.pone.0317940 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Napon Hiranburana und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: HIV Infections, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thai AIDS Society.
Abstract (Originalsprache)
People living with HIV (PLWH) exhibit heterogeneous immune responses, influenced by varying degrees of immune deficiency and viral suppression. The efficacy of COVID-19 vaccines in this population remains underexplored, particularly in those with low CD4 counts. This study assessed the antibody response in PLWH with CD4 T-cell levels ≤200 cells/mm 3 compared to those with higher levels, following a bivalent mRNA COVID-19 vaccine booster. All participants were on effective Antiretroviral therapy (ART) with virologic suppression and had received the booster more than a year after their last vaccination. Participants with lower CD4 counts exhibited reduced baseline Anti-RBD IgG titers. However, significant increases in Anti-RBD IgG and surrogate virus neutralization test (sVNT) levels were observed across both CD4 groups post-booster. Despite lower Geometric mean titer (GMT) in the low CD4 group, this group achieved a higher post-boost Anti-RBD IgG Geometric mean ratio (GMR), indicating a robust vaccine response facilitated by effective ART. Nonetheless, cross-neutralization against the circulating XBB variant was limited. Although individuals in the low CD4 group exhibited reduced protection at baseline, they showed significant increase in Anti-RBD IgG and sVNT levels across all CD4 counts after receiving the bivalent COVID vaccine booster.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Reserach Centre, Bangkok, Thailand.
- Faculty of Medicine, Center of Excellence in Tuberculosis, Chulalongkorn University, Bangkok, Thailand.
- Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Faculty of Medicine, Biostatistics Excellence Centre, Chulalongkorn University, Bangkok, Thailand.
- The Kirby Institute, University of New South Wales, Sydney, Australia.
ORCID-Profile: Lin-Fa Wang, Opass Putcharoen
Förderung
- Thai AIDS Society
Zitieren
APA
Hiranburana, N., Thippamom, N., Avihingsanon, A., Wacharapluesadee, S., Ubolyam, S., Kerr, S. J., Tan, C. W., Wang, L. F., & Putcharoen, O. (2025). Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination. PLOS One. https://doi.org/10.1371/journal.pone.0317940
Vancouver
Hiranburana N, Thippamom N, Avihingsanon A, Wacharapluesadee S, Ubolyam S, Kerr SJ, et al. Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination. PLOS One. 2025. doi:10.1371/journal.pone.0317940
BibTeX
@article{Hiranburana2025,
author = {Hiranburana, Napon and Thippamom, Nattakarn and Avihingsanon, Anchalee and Wacharapluesadee, Supaporn and Ubolyam, Sasiwimol and Kerr, Stephen J and Tan, Chee Wah and Wang, Lin-Fa and Putcharoen, Opass},
title = {Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0317940}
}
EUVIMED